Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | AADAC | P22760 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410320 | 0.88 | AR (0.72) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL2011994 | 0.87 | AR (0.82) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL11407111 | 0.86 | AR (0.85) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL8409001 | 0.86 | AR (0.81) | ARCYP3A4PGRCES2ABCB11 | |
| Hydroxyflutamide SCHEMBL3079778 | 0.86 | AR (1.00) | ARCYP3A4PGRCES2ABCB11 | |
| Hydroxyflutamide SCHEMBL29379312 | 0.86 | AR (1.00) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL8409337 | 0.85 | AR (0.79) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL14086876 | 0.85 | AR (0.83) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL8407213 | 0.85 | AR (0.79) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL7524151 | 0.84 | AR (0.81) | ARCYP3A4PGRCES2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331694-A1 | FAP-ACTIVATED COMPOUNDS FOR TREATMENT OF CANCER | UNITED STATES GOVERNMENT | 2023-10-19 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331694-A1 | FAP-ACTIVATED COMPOUNDS FOR TREATMENT OF CANCER | FAP, ACP3, FOLH1 | AR 402/4885CYP3A4 948/4885PGR 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.